Sapience Therapeutics, Inc.

[On Demand]
Search General Info
Search Education
Search Partnering Companies
Sapience Therapeutics is a clinical-stage biotechnology company focused on discovering and developing peptide-based therapeutics to previously "undruggable" targets for major unmet medical needs, particularly high mortality cancers.

Our drug candidates target protein-protein interactions (PPIs) that are responsible for either making the cells cancerous or dampening the immune response against tumors. These targets are considered undruggable because they are PPIs that reside inside of the cell, making them difficult to treat with small molecule drugs (which are incapable of disrupting PPIs) or antibodies (which are too big to enter the cell). We aim to combine the best features of these two drug classes by developing cell-penetrating peptides that can enter cells and disrupt these PPIs.
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
New York
Company HQ Country:
United States
Year Founded:
2015
Main Therapeutic Focus:
Lead Product in Development:
ST101
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):
10
Speaker
photo
President and CEO
Sapience Therapeutics Inc.